Jiang George, Charoenvit Yupin, Moreno Alberto, Baraceros Maria F, Banania Glenna, Richie Nancy, Abot Steve, Ganeshan Harini, Fallarme Victoria, Patterson Noelle B, Geall Andrew, Weiss Walter R, Strobert Elizabeth, Caro-Aquilar Ivette, Lanar David E, Saul Allan, Martin Laura B, Gowda Kalpana, Morrissette Craig R, Kaslow David C, Carucci Daniel J, Galinski Mary R, Doolan Denise L
Malaria Program, Naval Medical Research Center, Silver Spring, MD 20910-7500, USA.
Malar J. 2007 Oct 9;6:135. doi: 10.1186/1475-2875-6-135.
The present study has evaluated the immunogenicity of single or multiple Plasmodium falciparum (Pf) antigens administered in a DNA prime/poxvirus boost regimen with or without the poloxamer CRL1005 in rhesus monkeys. Animals were primed with PfCSP plasmid DNA or a mixture of PfCSP, PfSSP2/TRAP, PfLSA1, PfAMA1 and PfMSP1-42 (CSLAM) DNA vaccines in PBS or formulated with CRL1005, and subsequently boosted with ALVAC-Pf7, a canarypox virus expressing the CSLAM antigens. Cell-mediated immune responses were evaluated by IFN-gamma ELIspot and intracellular cytokine staining, using recombinant proteins and overlapping synthetic peptides. Antigen-specific and parasite-specific antibody responses were evaluated by ELISA and IFAT, respectively. Immune responses to all components of the multi-antigen mixture were demonstrated following immunization with either DNA/PBS or DNA/CRL1005, and no antigen interference was observed in animals receiving CSLAM as compared to PfCSP alone. These data support the down-selection of the CSLAM antigen combination. CRL1005 formulation had no apparent effect on vaccine-induced T cell or antibody responses, either before or after viral boost. In high responder monkeys, CD4+IL-2+ responses were more predominant than CD8+ T cell responses. Furthermore, CD8+ IFN-gamma responses were detected only in the presence of detectable CD4+ T cell responses. Overall, this study demonstrates the potential for multivalent Pf vaccines based on rational antigen selection and combination, and suggests that further formulation development to increase the immunogenicity of DNA encoded antigens is warranted.
本研究评估了在恒河猴中采用DNA初免/痘病毒加强免疫方案,单独或多次接种恶性疟原虫(Pf)抗原时,添加或不添加泊洛沙姆CRL1005的免疫原性。动物用PfCSP质粒DNA或PfCSP、PfSSP2/TRAP、PfLSA1、PfAMA1和PfMSP1-42(CSLAM)DNA疫苗的混合物在PBS中或与CRL1005配制后进行初免,随后用表达CSLAM抗原的金丝雀痘病毒ALVAC-Pf7进行加强免疫。使用重组蛋白和重叠合成肽,通过IFN-γ ELISpot和细胞内细胞因子染色评估细胞介导的免疫反应。分别通过ELISA和IFAT评估抗原特异性和寄生虫特异性抗体反应。用DNA/PBS或DNA/CRL1005免疫后,均证明对多抗原混合物的所有成分有免疫反应,与单独使用PfCSP相比,接受CSLAM的动物未观察到抗原干扰。这些数据支持对CSLAM抗原组合进行筛选。CRL1005制剂在病毒加强免疫前后对疫苗诱导的T细胞或抗体反应均无明显影响。在高反应性猴子中,CD4+IL-2+反应比CD8+T细胞反应更占优势。此外,仅在可检测到CD4+T细胞反应的情况下才检测到CD8+IFN-γ反应。总体而言,本研究证明了基于合理抗原选择和组合的多价Pf疫苗的潜力,并表明有必要进一步开发制剂以提高DNA编码抗原的免疫原性。